Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mesalamine ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1169)
•••
Comment by Duster340on May 04, 2021 10:52am
122 Views
Post# 33123162

RE:RE:RE:RE:RE:RE:Mesalamine ...

RE:RE:RE:RE:RE:RE:Mesalamine ...
MrMugsy wrote: So ... really what I'm getting at is ... the same academic study is underway for 340.
Find a more efficient carrier to replace 340 and create a new patent.
Then you have hope for IP protection (IP lead) farther into the future.

OTENA doesn't need to have a patent cliff in 2030/32 if we create a follow-on drug (again - the follow-on ideas was used by Dan in a conference call).

That increases the value of our company for future suitors - hence - why we have a lot of work before you get too close to a Big Pharma.

ATE has a lot of work - in order to prove to Big Pharma of the value in the IP.

Just my opinion.



Duster340 Writes:  this guy's opinion changes depending on what is going on with the stock, not to long ago when ate was over $7 he was saying big pharma was knocking on the door, could happen anytime.  now your opinion has changed to stay in tune with the current stock price. hahaha thats funny.. the reason we are down is because of p3 delay's and also the length of the trials. if p3 would have started on time they would have been half way through by now and likely a $8+ stock.
thats my opinion and that's what is going on.
glta
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities